mgd019
mAbexperimentalMulti-specific
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Dec 12, 2018 (NCT03761017)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Pancreatic Ductal · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Colorectal Neoplasms · Phase 2
- Drugs, Investigational · Phase 2
- Endometrial Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Immune Checkpoint Inhibitors · Phase 2
- Immune Checkpoint Proteins · Phase 2
- Immunotherapy · Phase 2
- Liver Neoplasms · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Rectal Neoplasms · Phase 2
- Risk · Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095278 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07223567 | Phase 2 | Apr 30, 2026 | Bayer, MacroGenics, University of Texas at Houston |
| NCT07137390 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2026 | University of Texas at Houston |
| NCT07071961 | Phase 2 | Jan 1, 2026 | Bayer, MacroGenics, University of Texas at Houston |
| NCT06730347 | Phase 2 | May 31, 2025 | MacroGenics |
| NCT05848011 | Phase 2 | Sep 28, 2023 | MacroGenics |
| NCT05475171 | Phase 2 | Dec 13, 2022 | MacroGenics, University of Texas at Houston |
| NCT05293496 | Phase 1 | Apr 19, 2022 | MacroGenics |
| NCT03761017 | Phase 1 | Dec 12, 2018 | MacroGenics |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MacroGenics | For profit | 7 | 4 | 2 | 2018 |
| University of Texas at Houston | Academic/Hospital | 4 | 4 | 1 | 2022 |
| Bayer | For profit | 2 | 0 | 1 | 2026 |
3 organizations
Page 1 / 1